|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61P 35/02 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61K 31/454 | (2006.01) | ||
| A61K 31/573 | (2006.01) |
| (11) | Number of the document | 3313528 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16738609.3 |
| Date of filing the European patent application | 2016-06-28 | |
| (97) | Date of publication of the European application | 2018-05-02 |
| (45) | Date of publication and mention of the grant of the patent | 2021-08-04 |
| (46) | Date of publication of the claims translation | 2021-10-11 |
| (86) | Number | PCT/US2016/039723 |
| Date | 2016-06-28 |
| (87) | Number | WO 2017/003990 |
| Date | 2017-01-05 |
| (30) | Number | Date | Country code |
| 201562185968 P | 2015-06-29 | US | |
| 201562239965 P | 2015-10-11 | US | |
| 201562262574 P | 2015-12-03 | US |
| (72) |
MULLIGAN, Christopher Lee , US
BARTLETT, Justin Blake , US
ROBBINS, Michael Darron , US
|
| (73) |
Bristol-Myers Squibb Company ,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Imunoterapinės dozavimo schemos, apimančios pomalidomidą ir anti-CS1 antikūną, skirtos vėžio gydymui |
| IMMUNOTHERAPEUTIC DOSING REGIMENS COMPRISING POMALIDOMIDE AND AN ANTI-CS1 ANTIBODY FOR TREATING CANCER |
| Payment date | Validity (years) | Amount | |
| 2025-05-22 | 10 | 231.00 EUR |
| 2026-06-28 |